Case number 1:22-cv-01216
AstraZeneca AB et al v. Alembic Pharmaceuticals Ltd. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Dec 30, 2022 | 12 | CONSENT JUDGMENT. Signed by Judge Richard G. Andrews on 12/30/2022. Associated Cases: 1:21-cv-00875-RGA, 1:22-cv-01216-RGA(nms) (Entered: 12/30/2022) (4) |
| Dec 30, 2022 | 13 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,300,065. (Attachments: # 1 Consent Judgment)(nms) (Entered: 12/30/2022) (Main Document) (1) |
| Dec 30, 2022 | 13 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,300,065. (Attachments: # 1 Consent Judgment)(nms) (Entered: 12/30/2022) (Consent Judgment) (4) |
| Dec 28, 2022 | 11 | PROPOSED Consent Judgment, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Silver, Daniel) Modified on 12/28/2022 (nms). (Entered: 12/28/2022) (4) |
| Oct 11, 2022 | 9 | ANSWER to 1 Complaint, and Defenses, by Alembic Pharmaceuticals Ltd., Alembic Pharmaceuticals, Inc..(Seaman, John) Modified on 10/11/2022 (nms). (Entered: 10/11/2022) (22) |
| Oct 11, 2022 | 10 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Alembic Limited for Alembic Pharmaceuticals Ltd.; Corporate Parent Alembic Global Holding SA, for Alembic Pharmaceuticals, Inc. filed by Alembic Pharmaceuticals Ltd., Alembic Pharmaceuticals, Inc.. (Seaman, John) (Entered: 10/11/2022) (1) |
| Sep 28, 2022 | 7 | DECLARATION of Service for Alembic Pharmaceuticals Ltd., by AstraZeneca AB, AstraZeneca Pharmaceuticals LP. (Attachments: # 1 Exhibits A-B)(Joyce, Alexandra) Modified on 9/28/2022 (nms). (Entered: 09/28/2022) (Main Document) (2) |
| Sep 28, 2022 | 8 | SUMMONS Returned Executed by AstraZeneca Pharmaceuticals LP, AstraZeneca AB.Alembic Pharmaceuticals, Inc. served on 9/20/2022, answer due 10/11/2022. (Joyce, Alexandra) (Entered: 09/28/2022) (2) |
| Sep 28, 2022 | 7 | DECLARATION of Service for Alembic Pharmaceuticals Ltd., by AstraZeneca AB, AstraZeneca Pharmaceuticals LP. (Attachments: # 1 Exhibits A-B)(Joyce, Alexandra) Modified on 9/28/2022 (nms). (Entered: 09/28/2022) (Exhibit A-B) (6) |
| Sep 16, 2022 | 1 | Complaint* (1) |
| Sep 16, 2022 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (lam) (Entered: 09/19/2022) (3) |
| Sep 16, 2022 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: No Earlier than August 2, 2022. Date of Expiration of Patent: 1/27/2036.Thirty Month Stay Deadline: 2/2/2025. (lam) (Entered: 09/19/2022) (2) |
| Sep 16, 2022 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,300,065. (lam) (Entered: 09/19/2022) (1) |
| Sep 16, 2022 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent AstraZeneca PLC for AstraZeneca AB, AstraZeneca Pharmaceuticals LP filed by AstraZeneca AB, AstraZeneca Pharmaceuticals LP. (lam) (Entered: 09/19/2022) (2) |
| Sep 16, 2022 | 6 | Summons Issued as to Alembic Pharmaceuticals Ltd. on 9/19/2022; Alembic Pharmaceuticals, Inc. on 9/19/2022. (Attachments: # 1 Summons Forms - Unsigned)(lam) (Entered: 09/19/2022) (Main Document) (2) |
| Sep 16, 2022 | 6 | Summons Issued as to Alembic Pharmaceuticals Ltd. on 9/19/2022; Alembic Pharmaceuticals, Inc. on 9/19/2022. (Attachments: # 1 Summons Forms - Unsigned)(lam) (Entered: 09/19/2022) (Summons Forms - Unsigned) (2) |
